A phase 2 open-label study to investigate the pharmacodynamics and clinical activity of IPI-504 in patients with castration-resistant prostate cancer stratified by prior chemotherapy

Trial Profile

A phase 2 open-label study to investigate the pharmacodynamics and clinical activity of IPI-504 in patients with castration-resistant prostate cancer stratified by prior chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2012

At a glance

  • Drugs Retaspimycin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Aug 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 14 Jul 2008 Status changed from recruiting to discontinued, as reported in an Infinity Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top